{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:02:37Z","timestamp":1704844957902},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2003,2,19]]},"abstract":"<jats:p>A remarkable development in personal injury litigation in recent years involves attempts to expand legal claims beyond existing injuries to anticipated future harms. Attorneys have begun to sue on behalf of individuals exposed to defective pharmaceutical products who have no current injury, but who may be at risk for developing one after a latency period. This strategy seeks to make drug manufacturers pay for<jats:italic>medical monitoring<\/jats:italic>, a court-ordered program that provides diagnostic tests to exposed individuals to facilitate early detection of adverse health effects. Because medical monitoring does not depend on the existence of an actual injury and large populations may be exposed, some commentators have warned that it has the potential to spiral out of control. We examine medical monitoring in the context of 2 major cases involving diet drugs and an oral hypoglycemic drug. We conclude that this expansion of tort law should be applied sparingly, but that the performance of courts to date in these cases gives cause for optimism. Judges appear to be paying close attention to sophisticated epidemiological, clinical, and cost-effectiveness considerations. Medical monitoring arms the courts with a new mechanism for addressing harms proactively rather than reactively, which could yield new victories for public health.<\/jats:p>","DOI":"10.1001\/jama.289.7.889","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T15:05:58Z","timestamp":1047999958000},"page":"889","source":"Crossref","is-referenced-by-count":5,"title":["Medical Monitoring for Pharmaceutical Injuries"],"prefix":"10.1001","volume":"289","author":[{"given":"David M.","family":"Studdert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troyen A.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"ref-jlm20034-1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women.","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","journal-title":"JAMA"},{"key":"ref-jlm20034-2","first-page":"B1","article-title":"Wyeth's Prempro problems galvanize plaintiffs' lawyers.","author":"Geyelin","year":"2002","journal-title":"Wall Street Journal"},{"key":"ref-jlm20034-3","first-page":"1C","article-title":"Prempro users, lawyers resort to legal remedy.","author":"Knopper","year":"2002","journal-title":"Chicago Tribune"},{"key":"ref-jlm20034-4","first-page":"1","article-title":"Client canvassing quickly launched for Prempro suits.","author":"Vogel-Short","year":"2002","journal-title":"New Jersey Lawyer"},{"key":"ref-jlm20034-5","first-page":"1D","article-title":"Here come the legal wranglings over Prempro.","author":"Rubin","year":"2002","journal-title":"USA Today"},{"key":"ref-jlm20034-6","article-title":"Adamu v Pfizer, No. 02-CV-2104 (D Conn filed October 27, 2002).","author":"Not Available"},{"key":"ref-jlm20034-7","first-page":"B3","article-title":"Class action suit over tobacco goes to trial after delays.","author":"Sayre","year":"2003","journal-title":"Advocate"},{"key":"ref-jlm20034-8","first-page":"815","article-title":"Asbestos litigation gone mad.","volume":"53","author":"Henderson","year":"2002","journal-title":"SC Law Rev"},{"key":"ref-jlm20034-9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pam.1037","article-title":"The economic impacts of the tobacco settlement.","volume":"21","author":"Cutler","year":"2002","journal-title":"J Policy Analysis Manage"},{"key":"ref-jlm20034-11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/publhealth.2000.21.issue-1","article-title":"The new public health litigation.","volume":"21","author":"Parmet","year":"2000","journal-title":"Annu Rev Public Health"},{"key":"ref-jlm20034-14","first-page":"1595","article-title":"Deterrence of medical errors: theory and evidence for malpractice reform.","volume":"80","author":"Mello","year":"2002","journal-title":"U Texas Law Rev"},{"key":"ref-jlm20034-15","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2307\/1123794","article-title":"The class certification of medical monitoring claims.","volume":"102","author":"Venugopal","year":"2002","journal-title":"Colum Law Rev"},{"key":"ref-jlm20034-16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2307\/1340397","article-title":"Of Frankenstein monsters and shining knights: myth, reality, and the class action problem.","volume":"92","author":"Miller","year":"1979","journal-title":"Harv Law Rev"},{"key":"ref-jlm20034-17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2307\/1123132","article-title":"The dilemma of the mass tort class action.","volume":"95","author":"Coffee","year":"1999","journal-title":"Colum Law Rev"},{"key":"ref-jlm20034-19","first-page":"296","article-title":"Individuals within the aggregate: relationships, representation, and fees.","volume":"71","author":"Resnik","year":"1996","journal-title":"NYU Law Rev"},{"key":"ref-jlm20034-20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2307\/1599829","article-title":"The regulation of entrepreneurial litigation: balancing fairness and efficiency in the large class action.","volume":"54","author":"Coffee","year":"1987","journal-title":"U Chic Law Rev"},{"key":"ref-jlm20034-21","first-page":"1925","article-title":"\u2018Shocked': mass torts and aggregate asbestos litigation after Amchem and Ortiz.","volume":"80","author":"Issacharoff","year":"2002","journal-title":"Texas Law Rev"},{"key":"ref-jlm20034-22","article-title":"Friends for All Children Inc v Lockheed Aircraft Corp, 746 F2d 816 (DC Cir 1984).","author":"Not Available"},{"key":"ref-jlm20034-23","article-title":"Ayers v Township of Jackson , 525 A2d 287 (NJ 1987).","author":"Not Available"},{"key":"ref-jlm20034-24","article-title":"Barnes v American Tobacco Co, 161 F3d 127 (3d Cir 1988).","author":"Not Available"},{"key":"ref-jlm20034-25","article-title":"Potter v Firestone Tire & Rubber Co, 863 P2d 795, 821 (Cal 1993).","author":"Not Available"},{"key":"ref-jlm20034-26","article-title":"In re Paoli Railroad Yard PCB Litigation, 35 F3d 717 (3d Cir 1994).","author":"Not Available"},{"key":"ref-jlm20034-27","article-title":"Redland Soccer Club Inc v Department of Army, 696 A2d 137 (Pa 1997).","author":"Not Available"},{"key":"ref-jlm20034-28","first-page":"849","article-title":"Medical surveillance damages.","volume":"63","author":"Slagel","year":"1988","journal-title":"Ind Law J"},{"key":"ref-jlm20034-29","first-page":"121","article-title":"Tort actions for medical monitoring: warranted or wasteful?","volume":"20","author":"Martin","year":"1995","journal-title":"Colum J Envtl Law"},{"key":"ref-jlm20034-30","first-page":"1","article-title":"Environmental torts.","volume":"46","author":"Brennan","year":"1991","journal-title":"Vand Law Rev"},{"key":"ref-jlm20034-32","article-title":"Bower v Westinghouse Electric Corp, 522 SE2d 424 (W Va 1999).","author":"Not Available"},{"key":"ref-jlm20034-33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0146-2806(99)90013-0","article-title":"Obesity drugs and the heart.","volume":"24","author":"Connolly","year":"1999","journal-title":"Curr Probl Cardiol"},{"key":"ref-jlm20034-34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"ref-jlm20034-36","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJM199809103391101","article-title":"The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.","volume":"339","author":"Khan","year":"1998","journal-title":"N Engl J Med"},{"key":"ref-jlm20034-37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.","volume":"339","author":"Jick","year":"1998","journal-title":"N Engl J Med"},{"key":"ref-jlm20034-38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo.","volume":"339","author":"Weissman","year":"1998","journal-title":"N Engl J Med"},{"key":"ref-jlm20034-39","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine.","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA"},{"key":"ref-jlm20034-40","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1001\/jama.286.16.2011","article-title":"Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine\/fenfluramine.","volume":"286","author":"Gardin","year":"2001","journal-title":"JAMA"},{"key":"ref-jlm20034-41","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1001\/jama.283.13.1738","article-title":"Heart valve disorders and appetite-suppressant drugs.","volume":"283","author":"Jick","year":"2000","journal-title":"JAMA"},{"key":"ref-jlm20034-42","article-title":"Jeffers v American Home Products Corp, No. 98-CV-20626, 1999 US Dist LEXIS 13228 (ED Pa August 26, 1999).","author":"Not Available"},{"key":"ref-jlm20034-43","article-title":"Birch v American Home Products Corp, No. 97-V-204 Civ (W Va February 11, 1999).","author":"Not Available"},{"key":"ref-jlm20034-44","article-title":"Earthman v American Home Products Corp, No. 97-10-03970 CV (Tex Dist Ct, October 14, 1998).","author":"Not Available"},{"key":"ref-jlm20034-45","article-title":"In re Diet Drugs Products Liability Litigation, MDL No. 1203, 2000 US Dist LEXIS 12275 (ED Pa February 1, 2001).","author":"Not Available"},{"key":"ref-jlm20034-46","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2307\/1342662","article-title":"Autonomy, peace, and \"put\" options in the mass tort class action.","volume":"115","author":"Nagareda","year":"2002","journal-title":"Harv Law Rev"},{"key":"ref-jlm20034-47","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJM199803263381302","article-title":"Effect of troglitazone in insulin-treated patients with type II diabetes mellitus.","volume":"338","author":"Schwartz","year":"1998","journal-title":"N Engl J Med"},{"key":"ref-jlm20034-48","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1056\/NEJM199803263381314","article-title":"Hepatic dysfunction associated with troglitazone.","volume":"338","author":"Watkins","year":"1998","journal-title":"N Engl J Med"},{"key":"ref-jlm20034-49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7326\/0003-4819-129-1-199807010-00008","article-title":"Two cases of severe clinical and histiologic hepatotoxicity associated with troglitazone.","volume":"129","author":"Gitlin","year":"1998","journal-title":"Ann Intern Med"},{"key":"ref-jlm20034-50","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.2337\/diacare.21.12.2140","article-title":"An autopsy case of troglitazone-induced fulminant hepatitis.","volume":"21","author":"Shibuya","year":"1998","journal-title":"Diabetes Care"},{"key":"ref-jlm20034-51","article-title":"In re Rezulin Products Liability Litigation, 210 FRD 61 (SDNY 2002).","author":"Not Available"},{"key":"ref-jlm20034-52","article-title":"Delaney v Warner-Lambert Co, No. BC227414, slip op (Cal Sup Ct January 15, 2002).","author":"Not Available"},{"key":"ref-jlm20034-53","article-title":"In re West Virginia Rezulin Litigation, No. 00-C-1180-H (W Va Cir Ct, December 5, 2001).","author":"Not Available"},{"key":"ref-jlm20034-54","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1023\/A:1005510132625","article-title":"Severe but reversible hepatitis induced by troglitazone.","volume":"45","author":"Schiano","year":"2000","journal-title":"Dig Dis Sci"},{"key":"ref-jlm20034-55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1572-0241.2000.01707.x","article-title":"Hepatotoxicity due to troglitazone.","volume":"95","author":"Kohlroser","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"ref-jlm20034-56","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/gut.44.5.731","article-title":"The natural history of histologically proved drug induced liver disease.","volume":"44","author":"Aithal","year":"1999","journal-title":"Gut"},{"key":"ref-jlm20034-58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2307\/1192289","article-title":"Scientific ignorance and reliable patterns of evidence in toxic tort causation.","volume":"64","author":"Cranor","year":"2001","journal-title":"Law Contemp Probs"},{"key":"ref-jlm20034-60","first-page":"521","article-title":"Medical monitoring: a viable remedy for deserving plaintiffs or tort law's most expensive consolation prize?","volume":"27","author":"Maskin","year":"2000","journal-title":"Wm Mitchell Law Rev"},{"key":"ref-jlm20034-61","article-title":"Hansen v Mountain Fuel Supply Co, 858 P2d 970 (Utah 1993).","author":"Not Available"},{"key":"ref-jlm20034-62","first-page":"1","article-title":"Rethinking medical monitoring.","volume":"64","author":"Klein","year":"1998","journal-title":"Brook Law Rev"},{"key":"ref-jlm20034-63","doi-asserted-by":"publisher","first-page":"942","DOI":"10.2307\/1122695","article-title":"Environmental liability and the limits of insurance.","volume":"88","author":"Abraham","year":"1988","journal-title":"Colum Law Rev"},{"key":"ref-jlm20034-64","first-page":"1057","article-title":"Preclusion, due process, and the right to opt out of class actions.","volume":"77","author":"Issacharoff","year":"2002","journal-title":"Notre Dame Law Rev"},{"key":"ref-jlm20034-10","volume-title":"Public Health Law: Power, Duty, Restraint","author":"Gostin","year":"2000"},{"key":"ref-jlm20034-12","volume-title":"Prosser & Keeton on the Law of Torts","author":"Keeton","year":"1984","edition":"5th ed."},{"key":"ref-jlm20034-13","doi-asserted-by":"crossref","DOI":"10.1353\/book.47484","volume-title":"Disease and Discovery: A History of the Johns Hopkins School of Hygiene and Public Health, 1916-1939","author":"Fee","year":"1987"},{"key":"ref-jlm20034-18","volume-title":"Class Action Dilemmas: Pursuing Public Goals for Private Gain","author":"Hensler","year":"2000"},{"key":"ref-jlm20034-31","volume-title":"Enterprise Responsibility for Personal Injury: Reporters' Study.","author":"Not Available","year":"1991"},{"key":"ref-jlm20034-57","volume-title":"Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case","author":"Angell","year":"1996"},{"key":"ref-jlm20034-59","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"ref-jlm20034-65","volume-title":"The Cost of Accidents: A Legal and Economic Analysis","author":"Calabresi","year":"1970"},{"key":"ref-jlm20034-35","unstructured":"Not Available. FDA analysis of cardiac valvular dysfunction with use of appetite suppressants Available at: http:\/\/www.fda.gov\/cder\/news\/slides. Accessed July 2002."},{"key":"ref-jlm20034-66","unstructured":"Not Available. Diet drug settlement Available at: http:\/\/www.ccnusa.com\/providers\/index.html. Accessed July 2002."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/195968\/jlm20034_889_894_1693255914.88864.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T13:59:27Z","timestamp":1704808767000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/195968"}},"subtitle":["Tort Law for the Public's Health?"],"short-title":[],"issued":{"date-parts":[[2003,2,19]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,2,19]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.289.7.889","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2,19]]}}}